Effectiveness_of_HIV_vaccine_final.pdf

Citeable URL: https://ir.library.oregonstate.edu/concern/articles/m039k943r

Descriptions

Attribute Name	Values
Creator	Jan Medlock Abhishek Pandey Alyssa S. Parpia Amber Tang Laura A. Skrip Alison P. Galvani
Abstract	The HIV pandemic continues to impose enormous morbidity, mortality and economic burdens across the globe. Simultaneously, innovations in antiretroviral therapy, diagnostic approaches and vaccine development are providing novel tools for treatment-as-prevention and prophylaxis. We developed a mathematical model to evaluate the added benefit of an HIV vaccine in the context of goals to increase rates of diagnosis, treatment, and viral suppression in 127 countries. Under status quo interventions, we predict a median of 49 million [1st and 3rd quartiles 44M, 58M] incident cases globally from 2015 to 2035. Achieving the UNAIDS 95–95–95 target was estimated to avert 25 million [20M, 33M] of these new infections, and an additional 6.3 million [4.8M, 8.7M] reduction was projected with the 2020 introduction of a 50%-efficacy vaccine gradually scaled up to 70% coverage. This added benefit of prevention through vaccination motivates imminent and ongoing clinical trials of viable candidates to realize the goal of HIV control.
Dichiarazione dei diritti	Copyright Not Evaluated